Skip Navigation


Journal of Intellectual Property Law & Practice Advance Access originally published online on May 9, 2006
Journal of Intellectual Property Law & Practice 2006 1(7):432-433; doi:10.1093/jiplp/jpl062
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/7/432    most recent
jpl062v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Padbury, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The author (2006). Published by Oxford University Press. All rights reserved.

Current Intelligence

Australian Full Federal Court clarifies best method disclosure obligation in Pfizer v Eli Lilly appeal

Mary Padbury
Blake Dawson Waldron Melbourne, Australia

The Australian Full Federal Court has found that (i) a patent applicant may amend the patent specification, until at least the date of grant, to include the best method known to the applicant at the date of filing and that (ii) there is no requirement that new best methods discovered after the date of filing of a complete patent specification be added by amendment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.